Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies ...
Company intends to advance felzartamab into late-stage development in Primary Membranous Nephropathy and other autoantibody-driven immune-mediated diseases Primary Membranous Nephropathy is a rare, ...
SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe ...
Povetacicept substantially reduced proteinuria with stable eGFR over 48 weeks in patients with IgAN or pMN, according to interim data from the phase 1/2 RUBY-3 trial. Povetacicept safely reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback